4.2 Article

Differential Response of MC3T3-E1 and Human Mesenchymal Stem Cells to Inositol Hexakisphosphate

Journal

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
Volume 30, Issue 4, Pages 974-986

Publisher

KARGER
DOI: 10.1159/000341474

Keywords

Inositol hexakisphosphate; Phytic acid; Osteoblast; Human umbilical cord mesenchymal stem cells (hUC-MSCs); Mineralization; Gene expression; IP6 kinase inhibitor

Funding

  1. INVEST IN SPAIN [C2_10_32]
  2. European Union
  3. Eureka-Eurostars Project [E! 5069 NewBone]
  4. Centre for the Development of Industrial Technology (CDTI) [CIIP20101024]
  5. Ministry of Science and Innovation of Spain

Ask authors/readers for more resources

Background: Inositol hexakisphosphate (IP6) has been found to have an important role in biomineralization. Methods: Because the complete mechanism of action of IP6 on osteoblasts is not fully understood and its potential use in the primary prevention of osteoporosis, we examined the direct effect of IP6 on cell viability and differentiation of MC3T3-E1 cells and on differentiation of human umbilical cord mesenchymal stem cells (hUC-MSCs). Results: We show that IP6 has different effects depending on the origin of the cell target. Thus, while IP6 decreased gene expression of osteoblast markers and mineralization in MC3T3-E1 cells without negatively affecting cell viability and ALP activity, an increase in gene expression of ALP was observed in hUC-MSCs committed to the osteoblastic lineage. This increasing effect of IP6 on ALP mRNA expression levels was reversed by the addition of a selective inhibitor of IP6 kinase, suggesting that the effect of IP6 might be due through its pyrophosphorylated derivatives. Besides, Rankl mRNA levels were decreased after IP6 treatment in MC3T3-E1 cells, pointing to a paracrine effect on osteoclasts. Conclusion: Our results indicate that IP6 has different effects on osteoblast differentiation depending on the cell type and origin. However, further studies are needed to examine the net effect of IP6 on bone formation and its potential as novel antiosteoporosis drug. Copyright (C) 2012 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available